Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- Check6 days agoChange DetectedThe page's location information was reorganized to include a top-level Locations section with Barcelona and Navarre, replacing the previous Barcelona and Navarre Locations entries. The revision version updated to v3.3.3 and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.3%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2.SummaryDifference0.0%

- Check34 days agoChange DetectedPublications section now states that publications are automatically filled from PubMed and displays revision: v3.3.1. The previous PubMed-origin wording and the older revision (v3.2.0) have been removed.SummaryDifference0.1%

- Check41 days agoChange DetectedThe site-wide government funding status notice has been removed. This administrative change does not affect the study details, eligibility criteria, or user actions on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check56 days agoChange DetectedResults for NCT03222856 have been posted, including efficacy and safety outcomes. The study record now shows updated completion and enrollment dates.SummaryDifference0.4%

- Check84 days agoChange DetectedUpgrade to v3.2.0 with a prominent operating-status notice and links; v3.1.0 is removed.SummaryDifference2%

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.